Israeli Multinational Pharmaceutical Company Settles FCPA Violations with SEC and DOJ for $519 Million

Federal Issues FCPA International SEC DOJ

On December 22, an Israeli multinational pharmaceutical company announced an agreement with the SEC and DOJ to resolve FCPA violations stemming from conduct in Ukraine, Mexico, and Russia, with a $519 million settlement and a deferred prosecution agreement. The company will pay more than $236 million in disgorgement and interest to the SEC, the second largest FCPA-related corporate disgorgement to date. As part of its agreement with the DOJ, the company will pay a $283 million criminal fine and enter into a three-year deferred prosecution agreement under the supervision of an independent compliance monitor.

Prior Scorecard coverage of the company's investigation can be found here.